Insider Trading Alert - RMD, PENN And PH Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, May 12, 2014, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $463.50 to $302,316,738.76.

Highlighted Stocks Traded by Insiders:

ResMed (RMD) - FREE Research Report

Sandercock Brett, who is Chief Financial Officer at ResMed, sold 5,000 shares at $50.00 on May 12, 2014. Following this transaction, the Chief Financial Officer owned 66,423 shares meaning that the stake was reduced by 7% with the 5,000-share transaction.

The shares most recently traded at $50.79, up $0.79, or 1.56% since the insider transaction. Historical insider transactions for ResMed go as follows:

  • 4-Week # shares sold: 4,290
  • 12-Week # shares sold: 19,890
  • 24-Week # shares sold: 81,577

The average volume for ResMed has been 1.1 million shares per day over the past 30 days. ResMed has a market cap of $7.1 billion and is part of the health care sector and health services industry. Shares are up 9.24% year-to-date as of the close of trading on Monday.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. The stock currently has a dividend yield of 1.97%. The company has a P/E ratio of 22.2. Currently, there are 4 analysts who rate ResMed a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RMD - FREE

TheStreet Quant Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, growth in earnings per share and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full ResMed Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates